Baseline Screening for JAK Inhibitors
Before initiating JAK inhibitor therapy, you must obtain complete blood count with differential, comprehensive metabolic panel (liver and renal function), lipid panel, hepatitis B and C serology (HBsAg, anti-HBs, anti-HBc, HCV antibody with reflex RNA if positive), tuberculosis screening, and assess cardiovascular/thromboembolic risk factors through detailed history. 1
Required Laboratory Tests
The 2025 expert consensus from the Annals of the Rheumatic Diseases establishes the following baseline laboratory requirements 1:
- Complete blood count with differential - Essential for detecting baseline cytopenias that may worsen with treatment
- Liver function tests - Most clinicians use AST/ALT at minimum, though full hepatic panel (bilirubin, albumin, alkaline phosphatase, GGT) provides comprehensive assessment
- Renal function tests - Creatinine and estimated GFR
- Lipid panel - JAK inhibitors can increase lipid levels during treatment
- CPK is NOT routinely needed at baseline, though should be checked if myalgia develops during therapy 1
Infectious Disease Screening
Hepatitis Testing (Mandatory)
You must screen all patients for hepatitis B and C 1:
- HBV surface antigen
- HBV surface antibody
- HBV core antibody
- HBV DNA testing (with or without, based on antibody results)
- HCV antibody with reflex to HCV RNA if positive
Tuberculosis Screening
Screen for tuberculosis risk factors and perform appropriate testing (QuantiFERON or PPD) based on patient history and local epidemiology 1.
Clinical Risk Assessment
Cardiovascular and Thromboembolic History
This is critically important given ORAL Surveillance trial findings 1. Specifically document:
- History of venous thromboembolism - Distinguish between provoked versus unprovoked events
- Prior cardiovascular events - MI, stroke, peripheral vascular disease
- Active cardiovascular risk factors - Hypertension, diabetes, hyperlipidemia
- Smoking history - Current smoking increases both cardiovascular and lung cancer risk
Malignancy Risk
Document 1:
- Prior malignancy history - Type, timing, treatment
- Current smoking status - Particularly relevant for lung cancer risk
- Family history of malignancy
Other Key Risk Factors
- Herpes zoster history - Most consistent safety signal across studies; vaccination should be considered 2
- Complicated diverticulitis history - Risk factor for GI perforation
- Baseline skin examination for non-melanoma skin cancer, especially in high-risk patients 1
Important Caveats
Age Alone Is Insufficient
Japanese evidence demonstrates that age by itself should not determine JAK inhibitor eligibility 2. Treatment outcomes are more strongly influenced by:
- Comorbidity burden
- Glucocorticoid exposure
- Laboratory abnormalities
- Individual patient risk factors
Rather than excluding older patients categorically, individualize decisions based on the specific risk profile above.
Avoid Common Pitfalls
- Do not rely on CRP/ESR for disease activity assessment once JAK inhibitors are started, as these markers decrease independently of clinical improvement through IL-6 pathway inhibition 1
- Multiple allergen sensitivities and elevated IgE >1000 may predict poorer response in atopic dermatitis patients 3, though this is disease-specific
Documentation Requirements
The baseline evaluation should explicitly document the presence or absence of contraindications and risk factors for:
- Major adverse cardiac events (MACE)
- Venous thromboembolism
- Serious infections
- Malignancy
This risk stratification guides both the decision to initiate therapy and the intensity of subsequent monitoring 1.